NCT06211335View on ClinicalTrials.gov

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Locally Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaRefractory Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Losartan

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (2)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

Colorado

RECRUITING

"University of Colorado Denver , Anschutz Medical Campus"

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Shyam S.D. Rao

OTHER